Merck remains a top Big Pharma name with strong leadership, rising sales, and high margins, despite regulatory fears and ...

Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...

Merck & Co. Inc. closed 40.46% short of its 52-week high of $134.63, which the company reached on June 25th.

The votes in favor of Merck’s shot are a sigh of relief after Kennedy gutted the panel and tapped replacements, some of whom ...

It boasts more than 80 programs in phase 2 or phase 3 studies. Even with a 25% success rate for these, that should translate ...

Merck's heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other ...

Iya Khalil, PhD, discusses Merck & Co.’s approach to artificial intelligence (AI), and success in applying the technology, ...

RFK Jr.’s vaccine panel endorsed Merck’s RSV shot for babies, easing fears that his stance might delay rollout.

Merck & Co., Inc. (NYSE:MRK) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company shared encouraging results from its Phase 3 HYPERION trial.

The company has raised its payouts for 14 consecutive years, and its nearly 89% growth over the last 10 years provides a ...

Merck & Co., Inc. (NYSE:MRK) is one of the Best Stocks to Buy for Dividends. Merck & Co., Inc. (NYSE:MRK) is a leading ...

A CDC advisory panel on Thursday voted 5-2 to recommend the use of a new preventative RSV therapy in babies, Merck’s ...